1 / 49

Psychophysiological Approach to Assessing Startle Response Conditioning and Extinction

Psychophysiological Approach to Assessing Startle Response Conditioning and Extinction. Tanja Jovanovic , PhD Grady Trauma Project Dept of Psychiatry & Behavioral Sciences, Emory University University of Southern California Technology and Innovation for the Prevention & Treatment of PTSD

aaron
Download Presentation

Psychophysiological Approach to Assessing Startle Response Conditioning and Extinction

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Psychophysiological Approach to Assessing Startle Response Conditioning and Extinction TanjaJovanovic, PhD Grady Trauma Project Dept of Psychiatry & Behavioral Sciences, Emory University University of Southern California Technology and Innovation for the Prevention & Treatment of PTSD October 31, 2012

  2. Grady Trauma Project: Risk and Resiliency www.gradytraumaproject.com PIs: Kerry Ressler, MD, PhD and Bekh Bradley, PhD

  3. Exposure to multiple types of trauma is the rule rather than the exception Trauma Exposures Often Include Childhood Abuse and Other Types of Family Violence

  4. Case example 1 (8622) T.D. is a 33 y/o AA female. From the age of six, she has sustained severe physical and emotional abuse by her father and repeated sexual abuse by her step brother. She was unwilling to talk about any of her traumas, but has significant symptoms of PTSD. She is also drinking about a 6 pack a day and is currently using cocaine. She has no close relationships with any of her family members. She has no friends, no hobbies, nor is she interested in leaving the house. Her current boyfriend has been taking care of her since her last suicide attempt a few weeks ago…this was her 3rd attempt. At that point the interview was discontinued and she was taken to be evaluated by a psychiatrist.

  5. Case example (8543) T.I. is a 25 y/o AA female. Until the age of 7, she lived with her mother and father, who were addicted to crack cocaine. She witnessed a number of violent fights between her parents. At age 8 she moved in with her grandmother. But while still living with her parents, she was exposed to a lot of neighborhood violence. As a 7 y/o, she survived a shootout between neighbors and dropped to the floor in the living room, trying to protect herself and her siblings from shots that came through the windows. She met current PTSD for this trauma. She still avoids the apartment complex at which this shooting happened. Today she has a great relationship with her children’s father. She sees her mother weekly (sober for 4 years). She speaks with her father monthly (sober for 2 years), and she is still close with her grandmother. She has no history of substance abuse.

  6. PTSD—The Disorder • Onset determined by traumatic event, but low rates of illness relative to trauma exposure: gene X environment risk factors • Heterogeneous: three major symptom clusters • Re-experiencing symptoms • Avoidance symptoms • Hyper-arousal symptoms • High rates of comorbidity with depression, other anxiety disorders, substance abuse

  7. GENES PTSD NEUROBIOLOGICAL BIOMARKERS ENVIRONMENT TRAUMA

  8. Neurobiological Biomarker:the “Holy Grail” of psychiatry? http://www.youtube.com/watch?v=9V7zbWNznbs

  9. Putative Biomarkers • HPA axis • Low basal cortisol/CRH • Hyper-suppression by dexamethasone • Low NPY • Disrupted sleep patterns • Elevated heart-rate • Reduced hippocampus volume • PACAP • Exaggerated startle response • IMPAIRED INHIBITION OF FEAR-POTENTIATED STARTLE Pubmed search of PTSD and biomarker returned 136 articles

  10. Neurobiological Biomarker Related to underlying neurobiology of the mental disorder Related to symptoms of the disorder Provide an objective measure of psychopathology Possible to model in preclinical studies—translational approach

  11. Biomarker: FEAR-POTENTIATED STARTLE

  12. Fear-potentiated startle: a laboratory measure of Fear

  13. http://cdmrp.army.mil/pubs/video/prm/norrholm_video.shtml

  14. Conditional Discrimination: AX+/BX- Acquisition: 3 blocks of 4 trials

  15. Conditional Discrimination: AX+/BX- Acquisition: 3 blocks of 4 trials Test: 3 trials

  16. AX+/BX- in healthy volunteers Jovanovic et al. (2005) Biological Psychiatry

  17. AX+/BX- in healthy volunteers * Jovanovic et al. (2005) Biological Psychiatry

  18. AX+/BX- in healthy volunteers * * Jovanovic et al. (2005) Biological Psychiatry

  19. Combat PTSD: Vietnam veterans p<0.01 p<0.05 p<0.05 p<0.05 Jovanovic et al. (2009) Psychiatry Research

  20. Civilian PTSD: Grady trauma p<0.01 p<0.05 Jovanovic et al. (2010) PNEC

  21. Combat PTSD vs. Acute Stress in Croatian sample p=0.001 Jovanovic et al. (in press)Depression & Anxiety

  22. Cognitive inhibition is normal in all groups p<0.001 p<0.001 p<0.001 p<0.001

  23. Simple Discrimination: A+/B- Acquisition: 3 blocks of 4 trials CS+ danger signal CS- safety signal

  24. Cognitive discrimination between CS+ and CS- p<0.001 p<0.001 p<0.001 CONTROL

  25. Cognitive discrimination between CS+ and CS- p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 CONTROL PTSD

  26. Startle discrimination between CS+ and CS- p<0.001 p<0.001 CONTROL

  27. Startle discrimination between CS+ and CS- p<0.05 p<0.01 p<0.001 p=0.06 p<0.001 CONTROL PTSD

  28. Correlation between startle to CS+ and CS- and PTSD symptoms DANGER SAFETY Glover et al (2011) Depression & Anxiety

  29. Fear Extinction CS+ LEVEL OF FEAR NUMBER OF EXTINCTION TRIALS TRAUMA: EXPOSURE THERAPY: COMBAT INTRUSIVE MEMORIES NUMBER OF THERAPY SESSIONS

  30. Extinction: A-/B- 10 min. after Acquisition Extinction: 6blocks of 4 trials CS+ danger signal—nonreinforced CS- safety signal

  31. Extinction in trauma controls

  32. Extinction is deficient in PTSD p<0.01 p<0.01 Norrholm et al (2011) Biol Psychiatry

  33. Fear inhibition is impaired in PTSD • PTSD is associated with impaired fear • inhibition using 3 fear-potentiated • startle paradigms • Impaired fear inhibition is a biomarker of • PTSD in different trauma populations

  34. Neurobiology of Fear Responses • Amygdala involved in expression of fear responses— • Fear Acquisition • Prefrontal cortex involved in inhibiting amygdala activity— • Fear Inhibition

  35. MRI Team: GTP Researchers: Ebony Glover, PhD NegarFani, PhD Sarah Spann Kerry Ressler, MD/PhD Emory Collaborators: Tim Ely, BA David Gutman, MD/PhD Georgia State Collaborators: Erin Tone, PhD

  36. PTSD<CONTROL

  37. PTSD < CONTROL

  38. Go/No go fMRI task X

  39. Go/No go fMRI task O

  40. Go/No go fMRI task X

  41. Contrast: No go > Go CONTROL> PTSD pFDRcorr=0.006 CONTROL>PTSD Stop>Go MNI coordinates: x=0, y=44, z=-8 Jovanovic, et al. (in press). Cortex.

  42. Correlations with fear inhibition Jovanovic, et al. (in press). Cortex.

  43. Potential applications • Identify at-risk individuals for early intervention • genes related to fear inhibition (GWAS) • Track treatment efficacy • Treatment target • Training intervention tasks (e.g. attention bias training) • Stimulation (e.g. DBS, TMS) • Developmental approach: emergence of risk phenotypes in traumatized pediatric populations

  44. Fear Inhibition as a Biomarker: IS IT USEFUL?

  45. Prediction of treatment outcome

  46. Prediction of treatment outcome More inhibition on transfer test

  47. Prediction of treatment outcome p=0.005 6/7 good inhibitors More inhibition on transfer test 9/11 poor inhibitors RESP NON-RESP

  48. Biomarkers: Neurobiological intermediate phenotypes Related to underlying neurobiology of the mental disorder Related to symptoms of the disorder Objective measure of psychopathology Possible to model in preclinical studies—translational approach

  49. Acknowledgements: • Emory University : • Kerry J. Ressler, M.D., Ph.D. • Bekh Bradley, PhD • Seth D. Norrholm, Ph.D. • Ebony Glover, PhD • NegarFani, PhD • Tim Ely • Allen Graham • Angelo Brown • Collaborators: • Barbara Rothbaum, Ph.D. • Erica Duncan, M.D. • Michael Davis, Ph.D. • Funding: National Institutes of Mental Health (MH071537, MH092576, MH098212), HHMI,NIH National Centers for Research Resources (M01 RR00039), Burroughs WellcomeFund, NARSAD, EMCF, • Atlanta Clinical and Translational Science Institute which is supported by the National Center for Advancing Translational Sciences of NIH (UL1TR000454).

More Related